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Abstract
Background: Cerebral malaria (CM) is a leading cause of malarial mortality resulting from infection by Plasmodium
falciparum. Treatment commonly involves adjunctive care and injections or transfusion of artemisinins. All artemisinins
that are in current use are metabolized to dihydroxyartemisinin (DHA), to which there is already some parasite
resistance. We used artemisone, a derivative that does not convert to DHA, has improved pharmacokinetics and anti-
plasmodial activity and is also anti-inflammatory (an advantage given the immunopathological nature of CM).
Methods: We examined controlled artemisone release from biodegradable polymers in a mouse CM model. This
would improve treatment by exposing the parasites for a longer period to a non-toxic drug concentration, high
enough to eliminate the pathogen and prevent CM. The preparations were inserted into mice as prophylaxis, early or
late treatment in the disease course.
Results: The most efficient formulation was a rigid polymer, containing 80 mg/kg artemisone, which cured all of the
mice when used as early treatment and 60% of the mice when used as a very late treatment (at which stage all control
mice would die of CM within 24 h). In those mice that were not completely cured, relapse followed a latent period of
more than seven days. Prophylactic treatment four days prior to the infection prevented CM. We also measured the
amount of artemisone released from the rigid polymers using a bioassay with cultured P. falciparum. Significant
amounts of artemisone were released throughout at least ten days, in line with the in vivo prophylactic results.
Conclusions: Overall, we demonstrate, as a proof-of-concept, a controlled-sustained release system of artemisone for
treatment of CM. Mice were cured or if treated at a very late stage of the disease, depicted a delay of a week before
death. This delay would enable a considerable time window for exact diagnosis and appropriate additional treatment.
Identical methods could be used for other parasites that are sensitive to artemisinins (e.g. Toxoplasma gondii and
Neospora caninum).
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Background
Malaria kills about 600,000 people annually, harms hun-
dreds of millions and causes tremendous economic
losses. Cerebral malaria (CM) is a leading cause of the
malarial mortality that may follow infection by Plasmo-
dium falciparum [1, 2]. CM has an immunopathological
etiology; it is induced by inflammatory responses against
plasmodia sequestered in the brain vasculature and at
the blood brain barrier [3, 4], and is also associated with
deleterious changes in brain metabolism [4–9].
In malaria-endemic countries many P. falciparum
strains have become resistant to most the conventional
antimalarial drugs, making development of alternative
drugs a necessity. The most recent successful anti-
malarial drugs that have been introduced are artemisinin
derivatives. However, these drugs (e.g. artemether and
artesunate) are converted in vivo to dihydroartemisinin
(DHA), which has a short half-life (less than an hour). In
contrast, another artemisinin derivative, artemisone,
does not metabolize to DHA, has a longer half-life,
increased anti-plasmodial activity, and thermal and
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metabolic stability [10, 11]. Compared to the other de-
rivatives it displays no neurotoxicity [12] but its embryo-
toxicity is in debate [13]. In a preclinical study artemi-
sone was profoundly superior to artesunate in treatment
of CM [14].
Artemisinins, including artemisone, possess both anti-
plasmodial and anti-inflammatory properties, an advan-
tage in the treatment of CM [14–16]. In a mouse model
of CM artemisone could prevent CM and inhibit the de-
velopment of the parasites. However, repeated injections,
at least twice a day over several days, were needed to ob-
tain a significant effect [14]. A similar necessity dictates
the mode of treatment of CM in humans [12]. In paral-
lel, patient non-compliance is limiting the use of artemi-
sinins, including artemisone. The problem of repeated
injections might partially be solved using artemisinin
combination therapies (ACTs) that are more effective
than individual drugs: combining a fast-acting artemisi-
nin derivative that rapidly clears a large proportion of
the parasites within its short pharmacological half-life,
with a much longer half-life partner drug that continues
the clearance while the artemisinin concentration falls to
sub-therapeutic levels [17]. Obviously, the use of ACTs
is applied to prevent the induction of resistance. How-
ever, recent incidences of resistance to ACTs have been
reported [18]. The phenomenon has necessitated at least
a two-fold increase in the artemisinin dose in ACT treat-
ment regimens to prolong exposure of blood-stage para-
sites to the drug [19, 20]. Artemisone would be
advantageous for ACTs because of its improved pharma-
cokinetics [10, 11]. In the current work, we examined a
novel option for improved treatment - the use of sus-
tained release formulations. To explore this in more de-
tail we studied the release of artemisone from solid
samples of a composite of biodegradable polyester and
artemisone and corresponding aqueous dispersions. We
hypothesized that this approach would improve the
treatment by exposing the parasite for a longer period to
a drug concentration sufficiently high to eliminate the
pathogens and prevent CM.
Methods
Parasites
Plasmodium berghei ANKA (PbA) strain (MRA-311,
CDC, Atlanta, GA, USA) was maintained in vivo by ser-
ial transfer of parasitized erythrocytes from infected to
naive mice. To avoid loss of virulence, infection was
renewed every six months by using frozen stabilates.
Plasmodium falciparum NF54-luc parasites that stably
and constitutively express luciferase were cultivated at
5% hematocrit in RPMI 1640 medium, 0.5% Albumax II
(Invitrogen, Carlsbad, California, USA), 0.25% sodium
bicarbonate, and 0.1 mg/ml gentamicin. Parasites were
incubated at 37 °C in an atmosphere of 5% oxygen, 5%
carbon dioxide and 90% nitrogen. Parasites were cul-
tured in media containing 4 nM WR99210 to select for
stable luciferase expression. Parasite viability assays were
performed either by measuring their luciferase activity
(see Bioassay below) or by direct microscopic observa-
tion of Giemsa (Sigma-Aldrich, St. Louis, USA) stained
blood smears.
Mice
Male C57BL/6 mice (7–8 weeks old) were purchased
from Harlan Laboratories (Rehovot, Israel). The mice
had free access to a standard diet and water, and they
were maintained on a 12/12-h automatically timed light/
dark cycle.
Induction of CM
The validity of the CM model in mice has been demon-
strated previously [21–23]. Mice were infected with
80,000 parasitized erythrocytes (this leads to CM in the
majority of mice). Parasitemia was monitored by blood
smears prepared from the tail vein, stained with Giemsa
and examined by light microscopy. Mice were monitored
for clinical signs of neuropathology that appear a few
days before death from CM (coat staring, hunching and
wobbly gait, about 5–6 days post-infection) [4, 14]. Mice
that developed further neurological symptoms such as
ataxia, paralysis and coma, drastic weight reduction and
depicted parasitemia below or about 20%, were consid-
ered to have fatal CM. At this stage death was inevitably
expected within 24 h and the mice were euthanized.
This assumption was confirmed by brain histological
sections [21, 24]. Typically, death of CM would occur at
day 8–9 post-infection at parasitemia below 20%. Mice,
which did not die of CM, did not show these symptoms
and would die of severe anemic malaria (AM) related to
high parasitemia, above 20%, one to two weeks later
[24]. Mice that were about to die of anemic malaria were
also euthanized. Mice that were treated with an anti-
malarial and consequently did not die of malaria
returned to a normal appearance.
Treatment
The artemisone was introduced in different concentra-
tions into PCL-b-MPEG dispersions or solid samples of
PCL-MPEG. The dispersions were intraperitoneally (IP)
injected and the solid polymers were inserted subcutane-
ously into the abdomen of mice anesthetized by
Ketamine/Xylazine injection, on different days before or
after inoculation of PbA. Treatment before infection was
performed to examine whether the in vivo retaining of
artemisone is sufficient to affect the course of infection.
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Polymer preparation
Blockpolymer PCL-MPEG was synthesized, according to
a previously published procedure [25]. Blockcopolymers
of PCL-MPEG were fabricated by different ratios of
PCL: MPEG. To create a homogeneous mixture of PCL-
b-MPEG and artemisone, different ratios of both
compounds were dissolved in small amounts of tetra-
hydrofuran (THF; p.a. ≥ 99.9%). After all particles were
dissolved, the solvent was completely evaporated. Using
a heat press at 65 °C the mixture was pressed into a
polytetrafluoroethylene matrix (internal size about 0.5 ×
10 × 20 mm3) and then cooled down to room
temperature under a second press at about 20 °C. The
polymers were sterilized by brief (5 s) washing in 70%
ethanol and exposure to UV for 45 min.
Preparation of artemisone containing aqueous
dispersions of PCL-b-MPEG
The dispersions were prepared according to a previously
published procedure [26]. In short: solvent displacement
(2.5% w/w PCL-b-MPEG; 2–2.5% w/w artemisione) took
place. One gram of the PCL-b-MPEG, with different
block length (a-d), and 20 mg artemisone were dissolved
in 26 ml THF and poured into 39 g water. To remove
the THF, the solution was stirred under a mild air
stream at 20 °C for 2 days. Dispersions (a-d) were for-
mulated in the following composition and were sterilized
by filtration through 0.22 μm filters. The dispersions
contained nanoparticles of about 100 nm.
a. PCL15,000-b-MPEG5,000, 2.5% Polymer, 2%
artemisone
b. PCL5,000-b-MPEG5,000, 2.5% Polymer, 2.5%
artemisone
c. PCL25,000-b-MPEG5,000, 2.5% Polymer, 2%
artemisone
d. PCL15,000-b-MPEG2,000, 2.5% Polymer, 2%
artemisone
The difference among the compounds is the hydrophilic-
lipophilic-balance, which describe the hydrophobic and
hydrophilic share of the polymer blocks in the block co-
polymer. MPEG is hydrophilic, biocompatible segment and
PCL is hydrophobic, biocompatible and biodegradable seg-
ment in the polymer. The subscript numbers show the mo-
lecular weight of the polymer block. For example, sample a
(PCL15,000-b-MPEG5,000) has a total molecular weight of
20,000 Da, at which the PCL has a molecular weight of
15,000 Da and MPEG has a molecular weight of 5000 Da.
By comparing these two molecular weights one can esti-
mate the degree to which a polymer is hydrophilic or lipo-
philic and while doing so the particle size of the block
copolymer. A higher molecular weight of the hydrophobic
PCL or a lower molecular weight of the MPEG leads to
larger particles. The particle size is important, especially for
surface degradation and consequently for the release of the
drug. The smaller particles should have a higher releasing
rate than the larger ones due to their higher surface-to-
volume-ratio.
The PCL-b-MPEG dispersions were not toxic to THP-
1 cells in vitro (Bubel, personal communication). Other
dispersions were prepared with higher concentration of
artemisone (5% w/w and 10%w/w) but the drug was
sedimented after removal of the organic solvent.
Macroscopic and histopathological evaluation
Surviving animals were sacrificed one and a half months
after treatment with polymers containing 2 mg artemi-
sone (80 mg/kg), and tissues from areas close to the in-
sertion place were fixed in 4% formaldehyde solution.
The tissues were processed into paraffin and 3 μm sec-
tions were stained with hematoxylin and eosin for histo-
logical evaluation. The examination parameters included
necrosis and inflammatory cell infiltration.
Bioassay for in vitro release of artemisone from PCL-b-MPEG
Released artemisone was quantified in a bioassay based
on two-day cultures of the artemisone sensitive P. falcip-
arum that stably expresses a luciferase gene (see para-
sites section above). PCL-MPEG samples were sterilized
by UV exposure and transferred to 1 mL RPMI 1640
medium in 24 well, Nunc disposable sterile plates that
were incubated at 37 °C. Once a day the medium was
collected and frozen until use; then, the polymers were
washed twice in 2 ml medium, 1 ml fresh medium was
added and the plates were returned to the incubator.
The collected supernatants in different dilutions were
examined for P. falciparum growth inhibition in Nunc
flat bottom 96-well plates (Nunc™ MicroWell™ 96-Well
Optical-Bottom Plates with Polymer Base; Nalge,
Rochester, USA). Luciferase activity was measured in
parasitized erythrocytes after removing 100 μl of the
medium, following addition of 100 μl Bright-GloH lucif-
erase reagent (Promega, Madison, USA) in a Fluoroskan
FL luminometer (Thermo, Paisley, UK).
Statistics
Experiments of the present study were performed at
least twice (with reproducible results) except the exam-
ination of the dispersions that was performed once be-
cause it yielded non-satisfactory results in comparison
with the solid polymers. Statistical analysis was per-
formed using GraphPad Prism, version 6.0.7 for
Windows (GraphPad Software, La Jolla, CA).
Development of parasitemia was compared using
Kruskal-Wallis test; delay (or prevention of death) was
compared using Log RANK analysis; linearity correlation
of parasitemia counted by microscopic observation and
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that measured by luminescence was tested using Pearson’s
correlation; Student’s t-test was performed to compare
inhibition of parasite development.
Results
Aqueous PCL-MPEG dispersions
Repeated IP injections of various artemisone-containing
aqueous PCL-b-MPEG dispersions revealed an effect of
shifting from CM death to anemic malaria (terminated
by death that occurred three weeks post-infection).
However, there was no complete elimination to non-
detectable parasitemia following the treatment. Despite
the significant results (especially in d), the outcome was
disappointing considering the early stage of the treat-
ment (Fig. 1). We did not continue using dispersions be-
cause it was impossible to increase the amount of
artemisone in them and because the other artemisone
formulations that were injected at the early stages of the
disease eliminated the parasites (see Fig. 2).
Solid samples of PCL-b-MPEG
Artemisone-containing solid polymers (0.5 mm thick,
5 × 20 mm; 0.5 or 2 mg artemisone in 50 mg polymers;
20 mg or 80 mg/kg, respectively) or blank polymers
were IP inserted on different days before or post-
inoculation (pi) with PbA.
Throughout the experiments all control untreated
(inserted with blank polymers) infected mice died of CM
on days 7–10 pi (in individual experiments within two
days). Mice that were treated with solid polymers con-
taining 20 and 80 mg/kg artemisone were completely
cured, if the polymers were inserted 1–2 days pi (Fig. 2).
Insertion of the polymers 6 days post-infection abolished
detectable parasitemia, as early as one day after the in-
sertion. A resulting latent stage that lasted a week in all
treated mice was followed by a relapse in 2/5 of the mice
treated with 20 mg/kg and 1/5 in the mice treated with
80 mg/kg. The non-relapsing mice completely recovered
(Fig. 3). Treatment on day 7 pi delayed death but was
Fig. 1 The effect of early treatment using artemisone in dispersions. a-d Different artemisone-containing dispersions (see Methods) at 6 mg/kg/injection.
The dispersions were intraperitoneally injected twice a day, one and three days post-parasite inoculation. Some of the dispersions prevented CM and
prolonged the survival time by about two weeks. These mice died of AM. We did not continue using dispersions because it was impossible to increase
the amount of artemisone in them and because other artemisone formulations that were injected at the early stages of the disease completely eliminated
the parasites (see Fig. 2)
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less efficient than the earlier treatment: after five days
of latency the disease relapsed in all mice treated with
20 mg/kg artemisone. 3/5 of these mice died of
anemic malaria and 2/5 died of CM. 3/5 mice treated
with 80 mg/kg drug died of CM and 2/5 were com-
pletely cured (Fig. 4). Polymers containing 80 mg/kg
artemisone inserted 7 days before parasite inoculation
were not prophylactic: 4/5 mice died of typical early
CM and 1/5 of anemic malaria 20 days pi. The re-
sults were improved with insertion of identical poly-
mers 4 days before infection. This treatment did not
prevent death from malaria; however, the treatment
changed the course of the disease and instead of
dying of CM all 5/5 mice succumbed to anemic mal-
aria, 22 days pi, about 2 weeks after the death of the
control group (Fig. 5).
One and a half months after insertion, the polymers
were not visible. Histology did not reveal any damage to
nearby tissues (data are not shown).
In vitro release of artemisone from solid polymers
The artemisone content of supernatants collected on
various days following in vitro release of the drug were
estimated by both luciferase assays and microscopic ob-
servation of stained blood smears, of the same cultures.
The results indicate an absolute correlation between the
two methods (Fig. 6). However due to its accuracy and
ease of performance, the luciferase assay was selected
for the P. falciparum quantitation.
The amount of released artemisone was further esti-
mated in cultures of P. falciparum that expresses the lu-
ciferase gene. Free artemisone standards were added for
comparison. Supernatants from media incubated with
blank solid polymers had no effect on P. falciparum de-
velopment (Fig. 7). In contrast, considerable amounts of
artemisone were released in vitro, spanning at least
13 days (Fig. 8). For example, a dilution of 1/140,000 of
supernatant collected on day 7 killed most of the para-
sites (meaning that the amount of released artemisone
was above 140 μg on that day). The ED50 of free artemi-
sone was estimated by identical methods and was about
1 ng/ml (concentrations of 0.1–10 ng/ml were estimated
in triplicates).
Discussion
Cerebral malaria is a major cause of malarial death and
its treatment is complicated because of the detrimental
role of the parasite and the deleterious immunopatho-
logical response. In view of the etiology of CM, both
anti-plasmodial and anti-inflammatory treatments are
necessary, in addition to adjunctive therapy [27, 28].
Currently, artemisinin derivatives are used as a first line
anti-malarial treatment [29]. Artemisone, being anti-
plasmodial and anti-inflammatory [15], was selected for
the current investigation. It is a recently synthesized ar-
temisinin derivative with longer in vivo half-life relative
to other derivatives [30], and has a superior anti-
plasmodial activity [10]. However, in mouse models re-
peated injections, twice a day for at least three days, are
necessary for a significant anti-plasmodial effect [14]. In
humans, a seven-days treatment against P. falciparum is
necessary to eliminate the parasites (and prevent CM,
providing that the parasites are not resistant to the drug)
[31]. Artemisinin derivatives are toxic at high concentra-
tions that cannot be accurately controlled by the usual
route of injections [13, 32]. Oral treatment may reduce
toxicity. However, due to very low absorption (and other
factors such as first pass metabolism), much higher
doses should be applied (limiting the use of the drugs
for economic reasons, unpublished data).
Although artemisone has improved pharmacokinetics
compared to other artemisinins, low patient compliance
may limit its use. As an alternative approach, we
incorporated the drug into different biodegradable
Fig. 2 The effect of early treatment using artemisone in solid
polymers. Polymers were subcutaneously inserted one day pi. Each line
represents one mouse. While all control mice died of CM, the
treatment significantly eliminated the parasites and all mice recovered.
Identical results were obtained after insertion of the polymers two days
pi (data not shown)
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preparations, to enable its slow release. The preparations
were inserted into mice as prophylactic therapy (for
proving the in vivo slow release of the drug) or as an
early or late treatment of experimental CM.
Previously, a limited number of experiments were per-
formed with the aim of obtaining improved activity of
artemisinins. Unfortunately, many of these experiments
were performed using artemisinin, which is no longer in
use in clinical treatment of malaria – only derivatives
are used. Some of these earlier experiments were aimed
at malaria treatment and some at cancer treatment. The
solubilization capacity of micelles of sodium dodecyl
sulphate (SDS) increased artemisinin solubility by 25-
fold [33]. Drug solubility studies of solid dispersions of
the poorly soluble artemisinin were developed using
polymer blends of polyvinylpyrrolidone (PVP) and poly-
ethylene glycol (PEG) with the aim of enhancing the
drug’s solubility and skin permeation in a model system.
The solubility and the permeation were enhanced, sug-
gesting a new route for malaria treatment [34]. Polyelec-
trolytes were deposited on artemisinin crystals but the
release of the artemisinin was measured only in vitro.
The half release time from the nanoparticles was about
10 h [35]. Artemisinin delivery and treatment could be
improved by using mixed non-ionic surfactants. The
results of size, zeta potential and polydispersity index of
niosomal formulation indicated that the size of the
resulting vesicles was below 200 nm, their surface charge
about -35 mV and they were monodisperse. The PEGy-
lated formulation had a stable release pattern and a
greater anti-tumor activity on cancer cell lines than the
free drug [36]. Ibrahim et al. report [37] the preparation,
characterization, and in vitro and in vivo biological
evaluation of biodegradable albumin-bound artemisinin
nanoparticles. The nanoparticles were prepared by a
combination of a bottom-up and a top-down processes
and were suitable for intravenous injection. The results
indicate improved anti-plasmodial activity of the nano-
particles over artemisinins in P. falciparum cultures
and in humanized severe combined immunodeficiency
(SCID) mice.
Another artemisinin derivative, artether, loaded in lipid
nanoparticles had improved bioavailability in rats. How-
ever, the artether’s half-life was only approximately three
hours [37]. Artesunate (the most used artemisinin de-
rivative) loaded in chitosan/lecithin nanoparticles was
adapted for controlled release. Oral treatment induced
protection in infected mice for about one month. How-
ever, to obtain the effect, the mice were treated twice a






















Fig. 3 The effect of late treatment, 6 days pi, using artemisone in solid polymers. Polymers were subcutaneously inserted six days pi. Each line
represents one mouse. All control mice died of CM within 10 days pi. Artemisone treatment eliminated the parasites to an undetectable level
and a latent period in all mice. 3/5 and 4/5 survived after 20 and 80 mg/kg treatment, respectively. These differences were significant
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post inoculation of the plasmodia (when minimal
amounts of parasites are present) [38]. Dwivedi and col-
leagues described the entrapment of artemisone in solid
lipid nano-particles and niosomes, and demonstrated
that the entrapment improved the efficacy of artemisone
against a melanoma cell line with negligible in vitro tox-
icity towards human keratinocytes [39].
Using a reliable mouse model of CM, throughout our
experiments all mice that did not receive drug treatment
died of CM. We used for treatment biodegradable for-
mulations, either artemisone-containing dispersions or
solid polymers. Dispersions at 6 mg/kg/injection were
intraperitoneally injected twice a day, one and three days
pi, to infected mice. Some of the dispersions prevented
CM and prolonged the survival of the treated mice by
about two weeks. The mice with extended survival died
later of AM. The small (50–100 nm) dispersions have
the advantages of easy sterilization by filtration and sim-
ple administration by injection; however, we did not
continue using them because it was impossible to in-
crease the amount of artemisone in the dispersions, re-
peated injections were a must, and other formulations
that were inserted at the early stages of the disease elim-
inated the parasites. Solid polymers could easily be
sterilized by UV exposure. Unlike the dispersions, the
solid polymers cured all mice treated by a single inser-
tion during the first few days pi. Later in the course of
infection, when symptoms of CM were obvious, it was
still possible to change the course of the disease by treat-
ment with the solid polymers: artemisone-containing
polymers, 20 and 80 mg/kg, cured most of the mice (60
and 80% cure, respectively) when used six days pi. Even
later, at seven days pi (all control mice would die of CM
within 24 h), insertion of 80 mg/kg artemisone in poly-
mers saved 40% of the mice. Most importantly, in all
cases of late treatment parasites were not detected for
about a week. In those mice that were not completely
cured a relapse followed the latent period. This delay is
vital because, if replicated in humans, it would enable at
least an extra week for exact diagnosis and appropriate
treatment. Misdiagnosis in malaria-infected persons and
the consequent lack of appropriate treatment often leads
to death or long-term cognitive defects [40]. Intraperito-
neal injection of artemisone had toxic effects (80 mg/kg
in 40 μl DMSO killed 25% of the mice, DMSO had no
effect, data not shown).
We also examined the solid polymers in prophylactic







14 19 20 288










6 7 8 18 20199 14 17






























Day post infection             
Fig. 4 The effect of late treatment, 7 days pi, using artemisone in solid polymers. Polymers were subcutaneously inserted seven days pi. Each line
represents one mouse. All control mice died of CM within 9 days pi. Delaying the treatment by one day, from 6 (Fig. 3) to 7 days pi, reduced the
following latent period; mice treated with 20 mg/kg did not survive and only 2/5 mice treated with 80 mg/kg artemisone survived the infection.
However, the treatment had a significant effect in reducing parasitemia to undetectable level during a latent period, and delaying mortality
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carried out seven days before infection, the released
artemisone had no effect on the course of the disease; in
contrast, CM prevention was demonstrated after poly-
mer insertion four days prior to the infection. These re-
sults enable an estimation of the amount of artemisone
that is released from the PCL-b-MPEG since it was re-
duced to an ineffective level after four days in vivo. In
parallel, we measured the amount of artemisone that
was released from the rigid polymers using an in vitro P.
falciparum bioassay. In this assay, we measured the lu-
minescence of transgenic parasites, an approach that
was in absolute correlation with microscopic observation
for parasite estimation. According to the reference arte-
misone quantification, at least 1 microgram artemisone/
day was released from the polymers until day 10 of the
bioassay. Later, there was a decline in release down to
Fig. 5 The effect of prophylactic treatment using 80 mg/kg artemisone
in solid polymers. Polymers were subcutaneously inserted four or seven
days before infection. Each line represents one mouse. Prophylactic
treatment seven days before infection had no effect on parasitemia or
survival. Treatment four days before infection prevented CM in all mice
but they went on to die with AM two weeks after the death of the
control mice
Fig. 6 Correlation between inhibition of in vitro development of
Plasmodium falciparum as measured by the luminometer versus
microscopic observation. Various concentrations of artemisone were
added to the cultures. The linear regression between the luminescence
detection and the microscopic observation indicates very high correlation
(R2 = 0.78, P < 0.0001)
Fig. 7 Inhibition of in vitro development of Plasmodium falciparum
by supernatants released from media incubated with blank solid
polymers. Samples were collected during three days from media
incubated in vitro with blank polymers (inserts 1 and 2) and tested
for their ability to kill P. falciparum in culture. *Supernatant dilution.
The initial parasitemia was 1% and final parasitemia was 2.2% at the
end of the experiment two days later. Fluorescence reading for the
control culture was 22,000 Relative Luminescence Units (RLU)
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non-significant quantities by day 13. Overall, there was a
parallel between the in vitro bioassay and the in vivo re-
sults that shows the suitability of the bioassay for pre-
dicting the amount of artemisone that would be released
in vivo. The amount of drug that we used would be toxic
if injected as a single dose [13, 32], illustrating another
advantage of the controlled release strategy.
Conclusions
Solid polymers that contain artemisone were inserted sub-
cutaneously and released the drug during at least a week
in non-toxic quantities that were sufficient to prevent or
delay CM in a mouse model, even when applied at a very
late stage of the disease. We demonstrate as a proof-of-
concept this controlled-sustained release system for safe
and effective treatment of malaria, emphasizing the advan-
tage of treatment of CM where conventional mode of
treatment is complicated. Similar methods could be used
for other parasites that are sensitive to artemisinins.
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